Longeveron Inc. – NASDAQ:LGVN
Founder-led company
Longeveron stock price today
$0.813
-0.93
-53.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Longeveron stock price monthly change
-60.14%
month
Longeveron stock price quarterly change
-60.14%
quarter
Longeveron stock price yearly change
+25.90%
year
Longeveron key metrics
Market Cap | 25.37M |
Enterprise value | 52.28M |
P/E | -3.19 |
EV/Sales | 42.78 |
EV/EBITDA | -2.91 |
Price/Sales | 49.24 |
Price/Book | 2.93 |
PEG ratio | 12.77 |
EPS | -9.62 |
Revenue | 978K |
EBITDA | -19.67M |
Income | -21.62M |
Revenue Q/Q | 96.41% |
Revenue Y/Y | -13.52% |
Profit margin | -1541.33% |
Oper. margin | -1476.51% |
Gross margin | 40.67% |
EBIT margin | -1476.51% |
EBITDA margin | -2011.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLongeveron stock price history
Longeveron stock forecast
Longeveron financial statements
| Jun 2023 | 217K | -5.63M | -2595.39% |
|---|---|---|---|
| Sep 2023 | 150K | -5.90M | -3936% |
| Dec 2023 | 63K | -6.02M | -9568.25% |
| Mar 2024 | 548K | -4.05M | -740.51% |
| Mar 2024 | 548K | -4.05M | -740.51% |
|---|---|---|---|
| Sep 2025 | 100K | -12.70M | -12709.29% |
| Oct 2025 | 200K | -804.34K | -402.17% |
| Dec 2025 | 200K | -804.34K | -402.17% |
Analysts Price target
Financials & Ratios estimates
| 2023-03-10 | -0.1 | -0.21 |
|---|---|---|
| 2023-05-12 | -0.19 | -0.22 |
| 2023-08-11 | -0.26 | -0.27 |
| 2023-11-10 | -0.24 | -0.28 |
| Jun 2023 | 17093000 | 5.83M | 34.11% |
|---|---|---|---|
| Sep 2023 | 11625000 | 4.99M | 42.95% |
| Dec 2023 | 12178000 | 5.33M | 43.82% |
| Mar 2024 | 9697000 | 6.65M | 68.64% |
| Jun 2023 | -4.60M | 2.45M | -86K |
|---|---|---|---|
| Sep 2023 | -4.55M | 3.82M | -50K |
| Dec 2023 | -3.99M | 1.56M | 5.41M |
| Mar 2024 | -3.08M | 14K | 63K |
Longeveron alternative data
| Aug 2023 | 19 |
|---|---|
| Sep 2023 | 19 |
| Oct 2023 | 19 |
| Nov 2023 | 19 |
| Dec 2023 | 19 |
| Jan 2024 | 19 |
| Feb 2024 | 19 |
| Mar 2024 | 23 |
| Apr 2024 | 23 |
| May 2024 | 23 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
Longeveron other data
0.66%
-1.48%
of LGVN is owned by hedge funds
138.06K
-311.80K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 5000 | 0 |
| Apr 2024 | 595744 | 0 |
| Dec 2024 | 0 | 1250 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BALUCH KHOSO director | Class A Common Stock | 1,250 | $2.07 | $2,589 | ||
Purchase | HARE JOSHUA director, 10 perc.. | Class A Common Stock | 42,553 | $2.35 | $100,000 | ||
Purchase | SOFFER ROCK director | Class A Common Stock | 31,915 | $2.35 | $75,000 | ||
Purchase | SOFFER ROCK director | Warrant (right to buy) | 31,915 | $2.35 | $75,000 | ||
Purchase | HARE JOSHUA director, 10 perc.. | Warrant (right to buy) | 42,553 | $2.35 | $100,000 | ||
Purchase | HASHAD MOHAMED WA'EL AHMED director, officer: Chief Execut.. | Class A Common Stock | 10,638 | $2.35 | $24,999 | ||
Purchase | HASHAD MOHAMED WA'EL AHMED director, officer: Chief Execut.. | Warrant (right to buy) | 10,638 | $2.35 | $24,999 | ||
Purchase | HARE JOSHUA director, 10 perc.. | Class A Common Stock | 106,383 | $2.35 | $250,000 | ||
Purchase | HARE JOSHUA director, 10 perc.. | Warrant (right to buy) | 106,383 | $2.35 | $250,000 | ||
Purchase | SOFFER ROCK director | Class A Common Stock | 106,383 | $2.35 | $250,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 11 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Joshua Michael Hare (1963) Co-Founder, Chief Science Officer & Chairman | $270,000 |
Mr. Geoff Green M.B.A. (1974) Chief Executive Officer | $234,330 |
| Mr. Paul T. Lehr J.D. (1968) International Executive Director, Gen. Counsel & Sec. | $182,650 |
Mr. James Clavijo CPA (1966) Chief Financial Officer & Treasurer | $171,810 |
-
What's the price of Longeveron stock today?
One share of Longeveron stock can currently be purchased for approximately $0.81.
-
When is Longeveron's next earnings date?
Unfortunately, Longeveron's (LGVN) next earnings date is currently unknown.
-
Does Longeveron pay dividends?
No, Longeveron does not pay dividends.
-
How much money does Longeveron make?
Longeveron has a market capitalization of 25.37M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 41.98% to 709K US dollars. Longeveron made a loss 21.41M US dollars in net income (profit) last year or -$0.28 on an earnings per share basis.
-
What is Longeveron's stock symbol?
Longeveron Inc. is traded on the NASDAQ under the ticker symbol "LGVN".
-
What is Longeveron's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Longeveron?
Shares of Longeveron can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Longeveron's key executives?
Longeveron's management team includes the following people:
- Dr. Joshua Michael Hare Co-Founder, Chief Science Officer & Chairman(age: 62, pay: $270,000)
- Mr. Geoff Green M.B.A. Chief Executive Officer(age: 51, pay: $234,330)
- Mr. Paul T. Lehr J.D. International Executive Director, Gen. Counsel & Sec.(age: 57, pay: $182,650)
- Mr. James Clavijo CPA Chief Financial Officer & Treasurer(age: 59, pay: $171,810)
-
Is Longeveron founder-led company?
Yes, Longeveron is a company led by its founder Dr. Joshua Michael Hare.
-
How many employees does Longeveron have?
As Jul 2024, Longeveron employs 23 workers.
-
When Longeveron went public?
Longeveron Inc. is publicly traded company for more then 4 years since IPO on 12 Feb 2021.
-
What is Longeveron's official website?
The official website for Longeveron is longeveron.com.
-
Where are Longeveron's headquarters?
Longeveron is headquartered at 1951 NW 7th Avenue, Miami, FL.
-
How can i contact Longeveron?
Longeveron's mailing address is 1951 NW 7th Avenue, Miami, FL and company can be reached via phone at +30 59090840.
Longeveron company profile:
Longeveron Inc.
longeveron.comExchange:
NASDAQ
Full time employees:
23
Industry:
Biotechnology
Sector:
Healthcare
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
1951 NW 7th Avenue
Miami, FL 33136
Miami, FL 33136
CIK: 0001721484
ISIN: US54303L1044
CUSIP: 54303L104
